Is Gufic BioScience overvalued or undervalued?

As of 29 October 2025, the valuation grade for Gufic BioScience has moved from very expensive to expensive. The company is currently considered overvalued based on its high price-to-earnings (PE) ratio of 54.86, a price-to-book value of 5.58, and an EV to EBITDA ratio of 27.64. These ratios indicate that the stock is priced significantly higher than its earnings and book value, which raises concerns about its valuation.
In comparison to its peers, Gufic BioScience's PE ratio is notably higher than Sun Pharma's 35.9 and Cipla's 23.68, both of which are also classified as expensive but offer more attractive valuations. Additionally, Gufic's PEG ratio of 0.00 suggests that there is no growth expected, which further supports the view of overvaluation. The company's recent stock performance has lagged behind the Sensex, with a year-to-date decline of 26.18% compared to the Sensex's gain of 8.78%, reinforcing the notion that the stock may not justify its current price.